干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现

免费注册账号
查看全文和研发动态、知识导航以及收藏您喜欢的数据等操作,您需要注册一个免费帐户并登录。

写笔记

您最近的笔记
Drug Name:rapamycin and analogs (head and neck squamous cell carcinoma), NIDCR
Regulatory Designations:     
Originator Company: National Institute of Dental and Craniofacial Research Active Companies: National Institute of Dental and Craniofacial Research; National Institutes of Health
Last Change Date: 2018-11-27

extract

inhibitors, for the potential prevention and treatment of head and neck squamous cell carcinoma (HNSCC), and also investigating other mTOR inhibitors, for the potential prevention of mucositis and hair loss in patients undergoing chemotherapy and stem cell transplantation [ 1395222 ], [ 1424377 ]. In August 2010, a phase I/II trial was initiated in HNSCC; in January 2013, enrollment was ongoing [ 1424377 ]; in May 2015, data from the trial were presented [ 1664652 ]. By September 2012, in vivo and


Other Drug Names:

mTOR inhibitors (epithelial stem cell loss/mucositis/head and neck squamous cell carcinoma), National Institute of Dental and Craniofacial Research; rapamycin and analogs (head and neck squamous cell carcinoma), NIDCR

Technologies

Small molecule therapeutic; Systemic formulation unspecified

Development Status (Current)

National Institute of Dental and Craniofacial Research: US: Discovery: Mucositis: 05-Sep-2012 National Institutes of Health: US: Discovery: Mucositis: 05-Sep-2012 National Institute of Dental and Craniofacial Research: US: Discovery: Alopecia: 05-Sep-2012 National Institutes of Health: US: Discovery: Alopecia: 05-Sep-2012 National Institute of Dental and Craniofacial Research: US: Phase 2 Clinical: Head and neck tumor: 31-Aug-2010 National Institutes of Health: US: Phase 2 Clinical: Head and neck tumor: 31-Aug-2010

Development Status (History)


Drug Development Phase

[Mucositis: Discovery: US Mucositis: Discovery: US Alopecia: Discovery: US Alopecia: Discovery: US Head and neck tumor: Phase 2 Clinical: US Head and neck tumor: Phase 2 Clinical: US]

Therapy Area:

Dermatologic; Gastrointestinal; Cancer


Highest Status

Phase 2 Clinical


Target-based Actions

mTOR inhibitor


Other Actions

Anticancer


Active Indications

Alopecia; Head and neck tumor; Mucositis